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It is currently estimated that over three
million new nonmelanoma skin can-
cers will be diagnosed in the United
States this year (Rogers et al., 2010).
The large majority is caused by chronic
excessive exposure to UVR. Because
of its public health relevance and the
need to understand the biologic impact
of UVR on the skin, there has been a
long-standing interest in the mecha-
nisms by which this form of radiant
energy causes skin cancer. Observa-
tions from this line of investigation
have led to a better understanding
of UV-induced skin cancer specifi-
cally and, more broadly, of cancer
in general. The concept of multistage
carcinogenesis, the influence of various
signal transduction pathways in cancer
development, the relationship of onco-
genes and tumor suppressor genes to
cancer, the contribution of DNA damage
and its repair to carcinogenesis, the
participation of the immune system in
tumorigenesis, and the identification of
new chemopreventive and therapeutic
agents have all benefited from obser-
vations about UVR-induced skin cancer.
UVR AND NONMELANOMA SKIN CANCER
The notion that chronic sun exposure
might be a cause of nonmelanoma skin
cancer was first described in 1894
when Unna (1894) reported that
sailors, who were chronically exposed
to large amounts of sunlight, were pre-
disposed to developing skin cancers,
primarily located on sun-exposed areas
of skin. Further characterization of the
photobiologic aspects relied largely
on experimental animal models. Using
mice, Findlay (1928) was the first to
show that chronic exposure to UVR
from an artificial light source could
cause squamous cell carcinomas
(SCCs). Decades later, Blum (1959)
showed that interposition of plate
glass, which selectively blocks UVB
wavelengths, between the light source
and the animals being irradiated
greatly reduced skin tumor incidence,
indicating that UVB was much more
potent at causing these malignancies
than UVA. Further characterization
of the wavelength dependence of
UV carcinogenesis revealed a 10-fold
decline in tumor production between
300 and 310nm and a 70-fold reduc-
tion in tumor incidence between
310 and 320nm (Freeman, 1975). The
animal model developed by Findlay
(1928), however, failed to produce
basal cell carcinomas (BCCs), an
accomplishment that was not achie-
ved until mutant mice genetically
deficient in the PTCH gene were chro-
nically exposed to UVR (Aszterbaum
et al., 1999). It is important to note that
wavelengths within the UVA have also
been shown to cause skin cancers, but,
on a per photon basis, require much
larger amounts of UVA radiation and
longer lengths of time to develop
(Strickland, 1986; Sterenborg and van
der Leun, 1990). However, when
combined with psoralens used in
clinical practice for the phototherapy
of psoriasis and other skin diseases
(Stern et al., 1984) and other medica-
tions (O’Donovan et al., 2005; Cowen
et al., 2010), UVA can be a much more
potent carcinogen.
DNA DAMAGE AND ITS REPAIR
The similarity between the wave-
lengths responsible for nonmelanoma
skin cancer (NMSC) and the action
spectrum for DNA damage led to the
conclusion that DNA damage might, at
least in part, be responsible for the
carcinogenic effects of UVR (Setlow
and Setlow, 1962). Aside from the
observation that the presumed action
spectrum for photocarcinogenesis is
similar to that for DNA damage,
several other lines of evidence lend
credence to the theory that DNA is a
relevant target for UVR, as it relates
to UV-induced NMSC. Much of this
derives from studies in the cells of
individuals with the genetic disease
xeroderma pigmentosum and from
experiments conducted in genetically
engineered mice with mutations similar
to those observed in xeroderma pig-
mentosum (de Vries et al., 1995). These
patients are predisposed to actinically
damaged skin and NMSC, and they
develop melanomas at an unusually
young age. Cleaver (1968, 1969) was
the first to show that these patients
have a defect in the repair of
UV-damaged DNA. Following expo-
sure to UVR, cell lines derived from
these patients have more mutations
and greater amounts of cell death and
chromosomal DNA damage than those
from normal individuals (Cleaver,
1968, 1969). Xeroderma pigmentosum
can be caused by mutations in several
genes, all of which are important in the
DNA repair pathway.
UVR produces multiple types of
DNA damage, including single-strand
breaks, pyrimidine dimers, purine
photoproducts, DNA–protein cross-
links, and (6-4) photoproducts, but the
greatest interest with respect to UV
carcinogenesis has been in cyclo-
butane pyrimidine dimers, which are
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the major DNA photoproduct formed
following UVR and which are repaired
in human skin primarily by nucleotide
excision repair. Cytosine to thymine
(C to T) mutations when two pyri-
midines lie next to each other—or, at
times, CC to TT mutations—are charac-
teristic of UV damage and are not
caused by other mutagens; as such,
these signature mutations have been
used to identify UV-induced DNA
damage (Brash et al., 1991).
STAGES OF PHOTOCARCINOGENESIS
The concept that cancer development
is a multistage process, in which
molecular and biochemical changes
accumulate in target cells in an orderly
sequence of events, originated in poly-
aromatic hydrocarbon skin carcinogen-
esis. During the initiation stage, DNA
damage occurs that produces inactivat-
ing mutations in selected tumor sup-
pressor genes or activating mutations in
oncogenes. These mutant keratino-
cytes are not clinically apparent, but
they undergo additional biochemical
changes in the promotion stage that
result in visible premalignant papillo-
mas. Of all the premalignant papillo-
mas, a small proportion acquire further
alterations that allow them to become
invasive carcinomas. Epstein was able
to show in mice that this same process
also occurs during photocarcino-
genesis, and that UVR can serve as
both a tumor initiator creating
mutations and a tumor promoter pro-
ducing other biochemical effects
(Epstein and Epstein, 1962; Epstein
and Roth, 1968).
UV AND TUMOR INITIATION
During the initiation stage, UV-induced
DNA damage produces mutations in
target keratinocytes. Those that result
in alterations in the p53 tumor sup-
pressor gene are found in both basal
cell and SCCs. Those that occur in the
sonic hedgehog pathway are critical for
producing BCCs. The importance of the
sonic hedgehog pathway as an initiat-
ing mutation in BCCs was first recog-
nized when it was observed that PTCH
gene mutations were present in patients
with basal cell nevus syndrome
(Johnson et al., 1996), an autosomal
dominant disorder in which patients
develop large numbers of BCCs. The
PTCH gene is an essential component
of the sonic hedgehog signaling path-
way. In the skin, the sonic hedgehog
pathway is important for epidermal
stem cell regulation, the generation of
sebaceous glands, and hair follicle
development. Studies have shown that
mutations in the PTCH gene, as well as
other genes in the sonic hedgehog
pathway, are present in most BCCs.
Many of the mutations in this pathway
contain UV signature lesions (Gailani
et al., 1996; Couve-Privat et al., 2002).
These findings in humans have been
corroborated in mouse models in
which the sonic hedgehog pathway is
dysregulated (Athar et al., 2004).
Mutations in p53 have been detected
in nearly 60% of cutaneous SCCs
(Brash et al., 1991) and up to half
of BCCs (Zhang et al., 2001). p53
has many biological activities. It has
been shown to activate DNA repair
enzymes, cause cell cycle arrest, and
induce apoptosis, all of which retard
photocarcinogenesis; UV-induced p53
mutations impair those functions
(Ziegler et al., 1994; Berg et al.,
1996). Restoration of mutant p53 to a
functional form of the protein has been
shown to inhibit UVB-induced skin
tumorigenesis in susceptible animal
models (Tang et al., 2007).
UV AND TUMOR PROMOTION AND
PROGRESSION
Many of the biochemical changes that
occur during the promotion stage of
UV carcinogenesis occur in response to
reactive oxygen intermediates. In ani-
mal models, it has been shown that a
variety of antioxidants present in diet-
ary products—green tea (Wang et al.,
1991), grape seed extract (Sharma
and Katiyar, 2010), silymarin (Katiyar,
2002)—can suppress UV-induced skin
cancer formation in animal models.
Another target of UVR is the enzyme
ornithine decarboxylase (ODC). ODC
is the rate-limiting step in polyamine
synthesis, which is involved in cell
proliferation. ODC activity is increased
following acute UV exposure, and
chronic exposure results in increased
basal levels of the enzyme (Lowe et al.,
1978; Hillebrand et al., 1990). BCCs
and SCCs can be prevented in
PTCH1þ / mice by inhibiting ODC
(Tang et al., 2004).
An additional biochemical change
that occurs during the promotion and
progression stages of UV carcinogen-
esis is increased expression of the
enzyme cyclooxygenase-2 (COX-2).
COX-2 is not constitutively expressed
in normal epidermis, but its synthesis is
increased markedly following UVR
exposure. It can be easily detected
in actinic keratoses (AKs), SCCs, and
BCCs (Fischer et al., 1999; An et al.,
2002). COX-2 is an enzyme required
for the formation of prostaglandin E2
from arachidonic acid. Prostaglandin
E2 has been associated with a broad
range of processes implicated in
UV-induced tumor promotion and
progression, including inflammation,
epithelial to mesenchymal transition,
angiogenesis, and immunosuppression.
COX-2 inhibitors have been successful
at preventing UV-induced skin cancers
in animal models (Fischer et al., 1999;
Pentland et al., 1999; An et al., 2002).
Epidemiological studies have also
shown that individuals who regularly
take nonsteroidal anti-inflammatory
drugs have a lower incidence of
cutaneous SCCs than those who do
not (Butler et al., 2005).
IMMUNOLOGY OF PHOTOCARCINOGENESIS
The skin tumors that develop following
chronic UV exposure are highly
antigenic in mice and in humans.
Immunosuppressive medications used
to treat organ transplant recipients
greatly increase the likelihood of
UV-induced skin cancers, and, in
addition, these cancers are more
aggressive than those observed in the
general population (Hoxtell et al.,
1977; Hartevelt et al., 1990). In spite
of the immunogenicity of UV-induced
skin tumors, they evade the host
immune defenses that have evolved to
eliminate neoplastic cells before they
become invasive malignancies (Kripke,
1974). This seeming contradiction was
resolved in a series of experiments
in which UV-induced tumors were
transplanted to syngeneic mice. When
E14 JUNE 2013 MILESTONES | CUTANEOUS BIOLOGY
the tumors were transplanted to mice
that had not received any UV exposure,
they initially grew but then regressed
once host immune defenses were
activated. In contrast, when the same
tumors were transplanted to syngeneic
mice that had been exposed to sub-
carcinogenic amounts of UVR, they
grew progressively and eventually
killed the recipients. The conclusion
from this study was that in addition to
producing mutations in skin cells UVR
impairs host immune responses that
are responsible for their eradication
before they can develop into clini-
cally apparent tumors. UVR, which
only reaches the superficial dermis,
was found to produce these effects by
perturbing the function of antigen-
presenting cells in the skin, stimulating
the production of regulatory T cells
and augmenting the production of the
immunosuppressive cytokine IL-10,
while at the same time diminishing the
production of IL-12 (Toews et al., 1980;
Elmets et al., 1983; Schwarz et al., 1996;
Shreeder et al., 1998; Loser et al., 2007).
The clinical relevance of the importance
of the immune system in UVR-induced
skin cancers was supported by observa-
tions in humans. Individuals who deve-
loped suppressed immune responses
following UVR were found to be signi-
ficantly more likely to develop NMSC
than those who were resistant to its
immunosuppressive effects (Yoshikawa
et al., 1990; Cooper et al., 1992).
CLINICAL RELEVANCE OF
PHOTOCARCINOGENESIS RESEARCH
Research identifying the mechanisms
by which UVR causes skin cancer have
served as the basis for new methods by
which NMSC can be prevented. The
use of sunscreens is recommended by
most physicians for the prevention of
skin cancer, although they are not
specifically approved by the US Food
and Drug Administration for that
purpose. There are published data to
indicate that their regular application
will reduce the incidence of AKs and
cutaneous SCCs. In subjects who pre-
viously have had AKs, sunscreens were
observed to diminish the incidence of
new AKs over a 7-month period of time
(Thompson et al., 1993). Sunscreens
have also been found to produce a 35%
reduction in cutaneous SCCs (Green
et al., 1999). There are no studies
achieving statistical significance that
have shown that sunscreens prevent
BCCs, although there is a trend in that
direction in one long-term follow-up
study (van der Pols et al., 2006).
T4 endonuclease V is a bacterial
DNA repair enzyme that removes
cyclobutane pyrimidine dimers
through base excision repair, thereby
helping to prevent mutations in
UV-irradiated keratinocytes. This agent
has been found to reduce the incidence
of AKs and BCCs in xeroderma
pigmentosum patients (Yarosh et al.,
2001).
GDC-0449 is an oral small-molecule
inhibitor that selectively interrupts acti-
vation of downstream hedgehog genes,
which, as was mentioned, is important
for the development of sporadic BCCs
and BCCs in basal cell nevus syn-
drome. This molecule is an effective
treatment for locally advanced and
metastatic BCC (Von Hoff et al.,
2009), and it causes regression and
prevention of BCCs in the basal cell
nevus syndrome (Tang et al., 2012).
Difluoromethylornithine, an agent
that irreversibly inhibits ODC, has
been shown to act on the promotion
and early progression of UV-induced
skin tumorigenesis in animal models
(Tang et al., 2004). In a skin cancer
prevention study of 291 participants
for 4 to 5 years, there was a statis-
tically significant 33% reduction in the
development of new BCCs in patients
treated with difluoromethylornithine
compared with placebo subjects
(Bailey et al., 2010).
Celecoxib is an oral medication that
inhibits COX-2 activity. In a multicenter,
double-blind, randomized phase II/III
trial of 240 patients, celecoxib was
shown to reduce the number of new
BCC and SCC by up to 60% over an
11-month period of time (Elmets et al.,
2010). In another trial, when celecoxib
was administered over a 24-month
period of time with a follow-up interval
of 36 months, there was a significant
reduction of new BCCs in patients with
the basal cell nevus syndrome, who at
the initiation of the study had less than
15 BCCs (Tang et al., 2010).
Retinoids promote differentia-
tion, growth arrest, and apoptosis of
epidermal keratinocytes. These agents
have been found to be effective
chemopreventive agents for NMSC in
high-risk individuals, including xero-
derma pigmentosum patients (Kraemer
et al., 1988), organ transplant
recipients (Bavinck et al., 1995), and
those having received large numbers of
psoralen photochemotherapy treat-
ments (Nijsten and Stern, 2003).
Finally, high-fat diets increase
inflammation, which is known to pro-
mote UV-induced skin cancers, possi-
bly by augmenting the synthesis
of tumor-promoting prostaglandins.
A randomized, controlled clinical trial
found that those individuals with
reduced dietary fat intake developed
significantly fewer new AKs and
NMSCs than those in whom dietary
fat intake was comparable to a normal
diet (Black et al., 1994).
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